Urinary vascular endothelial growth factor (VEGF) was determined by enzymelinked immunosorbent assay in 199 renal allograft recipients and 80 healthy controls. Urinary VEGF level did not change significantly during the first 8 weeks after transplantation in 119 patients with stable renal function and there were no abnormal histological findings (No-AR). In 67 patients with acute rejection, urinary VEGF was significantly higher (28.57 ± 6.21 pg/µmol creatinine) than in the No-AR patients (3.05 ± 0.45 pg/µmol creatinine) and healthy controls (2.87 ± 0.35 pg/µmol creatinine). At a cut-off point of 3.26 pg/µmol creatinine, sensitivity and specificity for diagnosis of acute rejection were 86.6 and 71.4%, respectively. The 13 patients with subclinical rejection excreted urinary VEGF (16.14 ± 4.09 pg/µmol creatinine) at a significantly higher level than No-AR patients (3.05 ± 0.45 pg/µmol creatinine). At a cut-off point of 4.69 pg/µmol creatinine, sensitivity and specificity for diagnosis of subclinical rejection were 84.6 and 79.8%, respectively. In conclusion, monitoring VEGF in urine might offer a new non-invasive way to detect acute and subclinical rejection in renal transplant recipients.
Introduction
Kidney transplantation is one of the treatments available for most patients with end-stage renal disease. Despite major advances in transplant immunology and pharmacotherapy that have led to an improvement in first-year renal graft survival, late graft loss continues to be a significant problem in renal transplantation. 1 Complications following renal transplantation, such as acute rejection, may lead to immediate loss of the graft or to chronic allograft nephropathy. 2 The diagnosis of acute rejection is suggested by clinical features, such as pain, oliguria and fever, and is best made based on the histology from percutaneous renal biopsy.
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and cannot be performed repeatedly over a short period. A non-invasive test that could be used for monitoring acute rejection would be of considerable value in supplementing biopsy.
Approximately 30% of urinary proteins are plasma proteins, the remaining 70% being produced in the kidneys. 4, 5 As a result, information on changes in urinary protein excretion may reflect the state of the kidneys. O'Riordan et al. 6 reported that the urine proteome in transplant recipients with acute rejection was significantly different from that of recipients with stable graft function. Voshol et al. 7 also believed that excreted proteins in the urine might constitute an early sign of the rejection process. The chemokine, MIG (monokine induced by interferon-γ; also known as chemokine C-X-C motif ligand 9 [CXCL9]), and interferon-γ-inducible protein 10 (IP-10; also known as CXCL10) in urine were shown to be markers of acute rejection in renal transplantation. 8 Messenger RNA (mRNA) for IP-10 was also significantly elevated in renal recipients with acute rejection. 9 Measurement of forkhead box P3 (FOXP3) mRNA in urine might offer another non-invasive means of improving the prediction of outcome of acute rejection of renal transplants. 10 Vascular endothelial growth factor (VEGF) is a heparin-binding growth factor that is secreted by epithelial cells, macrophages and myocytes. 11 In the human kidney, VEGF mRNA and protein are detected in glomerular podocytes, distal tubules and, to a lesser extent, in some proximal tubules. 12,13 VEGF stimulates endothelial cell proliferation and differentiation, increases vascular permeability, mediates endotheliumdependent vasodilatation, and promotes monocyte chemotaxis and the expression of adhesion molecules. 14 In addition, VEGF may amplify acute inflammatory reactions and promote leucocyte adhesion and tissue infiltration. 15 Exposure of endothelial cells and macrophages to VEGF activates the transcription factor, nuclear factor κB (NF-κB), which switches on the synthesis of proinflammatory cytokines and chemokines. 16, 17 The aim of the present study was to assess the excretion of VEGF into urine during acute kidney graft rejection. This might offer a new non-invasive method for the assessment of renal allografts.
Patients and methods

PATIENT SAMPLES AND IMMUNOSUPPRESSION
Urine samples from renal transplant patients were examined between June 2001 and December 2005. Fresh first-morning urine samples were collected from all patients every 2 weeks for 2 months after transplantation. In addition, urine samples were collected from patients scheduled for biopsy who had a serum creatinine concentration at least 25% above baseline and from patients who were to undergo protocol biopsy with stable renal transplant function within 4 -6 weeks after transplantation. Urine samples were also collected from 80 healthy individuals as controls.
Standard triple-drug maintenance immunosuppression comprised a calcineurin inhibitor (tacrolimus, trough level 5 -10 ng/ml; or cyclosporin, trough level 200 -300 ng/ml during the half year after transplantation) with either mycophenolate or azathioprine, and with prednisone in tapering doses from 80 to 10 mg/day within the first month after transplantation. Anti-rejection therapy after clinical and biopsy-proven diagnosis of acute rejection consisted of a 3-day course of methylprednisolone (6 -10 mg/kg per day). Lack of response to steroid treatment was defined as steroid-resistant W Peng, J Chen, Y Jiang et al. Urinary VEGF to detect acute renal allograft rejection acute rejection and, if this occurred, the patient was changed to treatment with muronomab-CD3 (Orthoclone OKT ® 3; Ortho Biotech, Bridgewater, NJ, USA) (5 mg/day). This therapy was scheduled for 5 -7 days. For patients diagnosed with humoral rejection, plasma exchange therapy was performed. A single experienced renal pathologist who was unaware of the results of the study used the Banff 97 3 classification to evaluate all biopsy specimens. Fresh urine samples were centrifuged using a D-37520 Sorvall ® Legend RT centrifuge (Heraeus, Hanau, Germany) for 10 min at 2500 rpm at 4°C and supernatant was stored at -80°C for later VEGF assay.
DETERMINATION OF VEGF IN URINE
Levels of VEGF were measured in urinary samples using a commercial human VEGF enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). All samples were tested in duplicate using a standardized ELISA technique, using undiluted urine samples. The VEGF levels were expressed per µmol urinary creatinine to correct for differences in urinary concentration.
STATISTICAL ANALYSIS
Statistical analysis was performed with the SPSS ® software package (version 14.0; SPSS Inc., Chicago, IL, USA). Since distribution of the data was non-parametric, comparisons of VEGF levels among different groups were performed using the Kruskal-Wallis test and the Mann-Whitney U test. A conventional receiver operating characteristic (ROC) curve was used to determine the sensitivities and specificities of VEGF measurements for patients with and without acute rejection or subclinical rejection. The area under the curve was also calculated. Results are expressed as mean ± SE unless otherwise stated. P < 0.05 was considered statistically significant.
Results
Among the 234 renal allograft recipients included in the study there were 102 suspected acute rejections, 67 of which were diagnosed as actual acute rejection (the remaining 35 were diagnosed as borderline change or acute tubular injury, or other diagnoses), and the 132 protocol biopsies resulted in 13 diagnoses of subclinical rejection. Demographic characteristics of these two groups and the 119 patients with stable renal function and no abnormal histological findings (No-AR) are summarized in Table 1 .
URINARY VEGF
In patients without acute rejection
In the 119 patients without acute rejection during the first 8 weeks after transplantation, levels of urinary VEGF did not change significantly, being (pg/µmol creatinine): 3.45 ± 0.44 at 2 weeks, 2.98 ± 0.49 at 4 weeks, 3.51 ± 0.81 at 6 weeks and 3.06 ± 0.85 at 8 weeks (Fig. 1 ).
In patients with acute renal allograft rejection Urinary VEGF was an indicator of acute renal allograft rejection in patients with acute renal allograft rejection. They were found to excrete urinary VEGF at a significantly higher level (28.57 ± 6.21 pg/µmol creatinine, 95% CI 16.18 -40.97 pg/µmol creatinine) than other patients (P < 0.001). Urinary VEGF concentrations did not differ significantly between patients with No-AR (3.05 ± 0.45 pg/µmol creatinine, 95% CI 2.17 -3.93 pg/µmol creatinine) and healthy controls (2.87 ± 0.35 pg/µmol creatinine, 95% CI 2.16 -3.57 pg/µmol creatinine) (Fig. 2) . 
Acute rejection Subclinical rejection
No-AR (n = 67) (n = 13) (n = 119) An ROC curve was constructed to determine the discriminatory power of VEGF levels for the diagnosis of acute rejection (Fig. 3) . The area under the ROC curve was 0.871 (95% CI 0.820 -0.921), which showed that VEGF was a suitable marker for the diagnosis of acute rejection. At a cut-off point of 3.26 pg/µmol creatinine, the sensitivity was 86.6% and the specificity was 71.4% (P < 0.001).
In patients with subclinical renal allograft rejection
Of 132 patients who received protocol biopsy and who had stable renal transplant function, 13 (9.8%) were diagnosed with subclinical rejection according to the Banff 97 3 classification. In these patients urinary VEGF was shown to be an indicator of subclinical renal allograft rejection, since these patients excreted urinary VEGF W Peng, J Chen, Y Jiang et al. Urinary VEGF to detect acute renal allograft rejection (16. 14 ± 4.09 pg/µmol creatinine, 95% CI 7.21 -25.06 pg/µmol creatinine) at a significantly higher level than No-AR patients (P = 0.022). Patients with subclinical rejection had non-significantly lower VEGF values than patients with acute rejection (data not shown).
The ROC curve showed the sensitivity and specificity for various cut-off points for levels of VEGF to determine the diagnosis of subclinical rejection (Fig. 4) . The area under the ROC curve was 0.819 (95% CI 0.662 -0.976). The cut-off point that maximized the combined sensitivity and specificity for VEGF was 4.69 pg/µmol creatinine. At this threshold, the sensitivity for the diagnosis of subclinical rejection was 84.6% and specificity was 79.8% (P < 0.001).
Discussion
Histological examination of renal allograft tissue is an accepted standard for diagnosing acute rejection; however, because of inadequate sample size and sampling error, there have been conflicting results regarding histological findings. Serial surveillance biopsies of the transplant would undoubtedly detect some instances of subclinical rejection, but this may be precluded by cost and complication-related issues. It would be desirable to use a noninvasive technique to allow reduction of the use of biopsy for the diagnosis of acute and subclinical rejection. Some studies have associated acute rejection with cytokines, such as adhesion molecules 18 and chemokines, 8 and shown that monitoring the levels of these cytokines in blood and urine is helpful in the treatment of renal allograft recipients. 19 In the present study we investigated the relevance of the concentration of VEGF in urine for the diagnosis of acute and subclinical rejection.
In the present work a significant difference was demonstrated in the urinary excretion of VEGF between patients with No-AR and those with acute or subclinical rejection. Patients with No-AR displayed VEGF concentrations which had no statistical difference in the urine at different times during the early period (8 weeks) after transplantation. VEGF might, therefore, be a suitable marker to monitor renal function after transplantation.
The role of VEGF in the normal kidney has and macrophages are important in the development of the rejection process. 21 VEGF also causes monocyte attraction to the tubulointerstitium through leucocyte and monocyte adhesion, by increasing both the surface expression of P-selectin and the chemotactic ability of macrophages. 22 With increasing expression of VEGF, infiltration of macrophages and leucocytes is facilitated by increasing capillary permeability, and leucocyte and monocyte adhesion are increased through increased surface expression of P-selectin on the endothelium. 22 VEGF is induced in the tissues by hypoxia, which is an inevitable consequence of the transplantation process. Increased VEGF production promotes endothelial permeability and leucocyte migration into the allograft, which may lead to a clinically recognized rejection episode. Gene polymorphisms of VEGF are associated with increased expression of VEGF and the risk of acute rejection. 23 VEGF is, therefore, potentially an important cytokine in the pathogenesis of acute rejection. We observed elevated urinary levels of VEGF in patients with acute and subclinical rejection. Patients with acute rejection could be distinguished from those with No-AR on this basis. At a urinary VEGF concentration of 3.26 pg/µmol creatinine, sensitivity and specificity for the diagnosis of acute rejection were 86.6% and 71.4%, respectively. Similarly, among patients with stable graft function, patients with subclinical rejection could be distinguished from those without graft injury. At a urinary VEGF concentration of 4.69 pg/µmol creatinine, sensitivity and specificity for the diagnosis of subclinical rejection were 84.6% and 79.8%.
The development of non-invasive techniques for the detection of acute rejection is a major goal of the transplantation community. The ongoing, but unrecognized, process of subclinical rejection is thought to determine the longterm survival of the allograft. The monitoring of VEGF in urine may prove to be an important new non-invasive method for the detection of acute and subclinical rejection. Furthermore, measurement of VEGF in urine is a simple, inexpensive method for routine clinical monitoring after kidney transplantation.
